Kumar Shantanu, Gao Lu, Yeagy Brian, Reid Tony
University of California, San Diego, Department of Hematology and Oncology, Moores UCSD Cancer Center, 3855 Health Sciences Drive, La Jolla, California, 92093, USA.
Curr Opin Mol Ther. 2008 Aug;10(4):371-9.
Oncolytic viruses possess an inherent trophism for tumor cells or have been engineered in a variety of ways to selectively replicate in and destroy cancer cells. Because of the unique mode of tumor destruction, oncolytic virotherapy has the potential to augment the antineoplastic activity of chemotherapy and radiation therapy. Many oncolytic viruses, such as adenovirus, HSV, vaccinia, measles, reovirus, Newcastle disease virus and coxsackie virus, have entered into clinical trials and their efficacy and safety have been demonstrated with few, minor, side effects. Data obtained from several clinical trials of the oncolytic adenovirus, ONYX-015, in patients with cancer have been described in detail. Some preclinical studies of oncolytic viruses have demonstrated promising results, mainly when administered in combination with chemotherapeutic drugs. In this review, the clinical use of oncolytic viruses in combination with chemotherapy and radiation therapy, and future directions to enhance the efficacy of oncolytic virotherapy, are discussed.
溶瘤病毒对肿瘤细胞具有内在的嗜性，或者已经通过多种方式进行改造，以在癌细胞中选择性复制并破坏癌细胞。由于独特的肿瘤破坏模式，溶瘤病毒疗法有可能增强化疗和放疗的抗肿瘤活性。许多溶瘤病毒，如腺病毒、单纯疱疹病毒、痘苗病毒、麻疹病毒、呼肠孤病毒、新城疫病毒和柯萨奇病毒，已经进入临床试验，并且其疗效和安全性已得到证实，副作用很少且轻微。从溶瘤腺病毒ONYX - 015在癌症患者中的几项临床试验中获得的数据已被详细描述。溶瘤病毒在一些临床前研究中已显示出有前景的结果，主要是在与化疗药物联合使用时。在这篇综述中，讨论了溶瘤病毒与化疗和放疗联合使用的临床应用，以及提高溶瘤病毒疗法疗效的未来方向。
